- Summer Street is out in defense of Rockwell Medical (RMTI -19.8%) amid a sell-off triggered (apparently) by comments out of Brean's Jonathan Aschoff.
- "Buy the weakness," Summer Street's Carol Werther says, adding that "Triferic did reduce ESA use by 74% in hypo-responders, 8.5% from baseline."
- Werther continues: "The pivotal CRUISE design was put together with [the] FDA, achieved the primary endpoint on efficacy, [and] was statistically significant in both trials."
- "The analyst who initiated on RMTI did not even speak to [the company] prior to putting out his negative research report," Werther says, incredulous.
Summer Street defends Rockwell Medical after negative Brean note
Dec 17 2013, 13:29 ET